Empagliflozin and metformin synergy in proximal tubular epithelial cells: does the combination alleviates hyperglycaemia-induced metabolic stress?

GALUŠKA, David, Lukáš PÁCAL, Katarína CHALÁSOVÁ and Kateřina KAŇKOVÁ. Empagliflozin and metformin synergy in proximal tubular epithelial cells: does the combination alleviates hyperglycaemia-induced metabolic stress? In EASD. 2023.

Basic information

• Original name: Empagliflozin and metformin synergy in proximal tubular epithelial cells: does the combination alleviates hyperglycaemia-induced metabolic stress?
• Name in Czech: Synergie empagliflozinu a metforminu v proximálním tubulu: ovlivňuje tato kombinace stress způsaobený hyperglykémií?
• Authors: GALUŠKA, David (203 Czech Republic, belonging to the institution), Lukáš PÁCAL (203 Czech Republic, belonging to the institution), Katarína CHALÁSOVÁ (703 Slovakia, belonging to the institution) and Kateřina KAŇKOVÁ (203 Czech Republic, belonging to the institution).
• Edition: EASD, 2023.

Other information

• Original language: English
• Type of outcome: Conference abstract
• Field of Study: 30202 Endocrinology and metabolism
• Country of publisher: Germany
• Confidentiality degree: is not subject to a state or trade secret
• WWW: URL
• Organization unit: Faculty of Medicine
• Keywords in English: Empagliflozin; metformin; synergy; proximal tubular epithelial cells
• Tags: International impact

Abstract

Metformin remains the drug of first choice in type 2 diabetes mellitus (T2DM) worldwide since its beneficial metabolic effects are known for a long time.

Links

• LX22NPO5104, research and development project: Name: Národní institut pro výzkum metabolických a kardiovaskulárních onemocnění (Acronym: CarDia)

Investor: Ministry of Education, Youth and Sports of the CR, 5.1 EXCELES